Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Gene | KIT |
| Variant | exon11 |
| Impact List | unknown |
| Protein Effect | unknown |
| Gene Variant Descriptions | KIT exon 11 (amino acids 550-592) indicates an unspecified mutation within the juxtamembrane domain has occurred in exon 11 of the KIT gene. |
| Associated Drug Resistance | |
| Category Variants Paths |
KIT mutant KIT exon11 |
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT06208748 | Phase II | PLX9486 + Sunitinib | SARC044: A Phase II Trial of Bezuclastinib in Combination With Sunitinib in Patients With GIST | Active, not recruiting | USA | 0 |
| NCT07171203 | Phase I | Dalfampridine + Imatinib | Neoadjuvant Imatinib and Fampridine in KIT Mutant Gastrointestinal Stromal Tumor | Not yet recruiting | USA | 0 |
| NCT02638766 | Phase II | Regorafenib | Single Agent Regorafenib in First-line for Metastatic/Unresectable KIT/PDGFR Wild Type GIST (REGISTRI) | Completed | ITA | FRA | ESP | 0 |
| NCT02465060 | Phase II | Erdafitinib Trametinib Crizotinib Sapanisertib Fexagratinib Dasatinib Osimertinib Palbociclib Capivasertib Larotrectinib Ulixertinib Nivolumab + Relatlimab Copanlisib Sunitinib Nivolumab Pertuzumab + Trastuzumab Ipatasertib Dabrafenib + Trametinib Binimetinib Adavosertib Afatinib Defactinib GSK2636771 Vismodegib Ado-trastuzumab emtansine Taselisib | Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) | Active, not recruiting | USA | 2 |
| NCT04116541 | Phase II | Alectinib Dabrafenib + Trametinib Cabozantinib Avapritinib | A Study Evaluating the Activity of Anti-cancer Treatments Targeting Tumor Molecular Alterations/Characteristics in Advanced / Metastatic Tumors. (MegaMOST) | Recruiting | FRA | 0 |
| NCT05957367 | Phase Ib/II | Inlexisertib + Ripretinib | A Study of Inlexisertib (DCC-3116) in Combination With Anticancer Therapies in Participants With Advanced Malignancies | Recruiting | USA | 0 |
| NCT05734105 | Phase III | Ripretinib Sunitinib | A Study of Ripretinib Vs Sunitinib in Patients with Advanced GIST with Specific KIT Exon Mutations Who Were Previously Treated with Imatinib (INSIGHT) | Recruiting | USA | POL | NOR | NLD | ITA | GBR | FRA | ESP | DEU | CAN | BRA | AUS | 3 |
| NCT05734105 | Phase III | Ripretinib Sunitinib | A Study of Ripretinib Vs Sunitinib in Patients with Advanced GIST with Specific KIT Exon Mutations Who Were Previously Treated with Imatinib (INSIGHT) | Recruiting | USA | POL | NOR | NLD | ITA | GBR | FRA | ESP | DEU | CAN | BRA | AUS | 3 |